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Background
> Australia has the highest skin cancer in the world:
 Malignant Melanoma
 Non-Melanomic Skin Cancer (NMSC)
• Basal cell carcinoma (BCC)
• Squamous cell carcinoma (SCC)
> Most common cancer: 2 in 3 Australians can expect to 
have NMSC treated by the age of 70 
> Most expensive cancer in Australia: more than $294 
million spent annually on the diagnosis and treatment 
of skin cancer
> Most significant component of skin cancer: 
preventable
Public Health Campaigns
> Existence for decades
> “Slip Slop Slap” Campaign in Victoria in early 1980s
> Rolled into a multi-faceted skin cancer prevention 
program: SunSmart
> National initiative delivered primarily through Cancer 
Councils across Australia under the brand name
Investment in SunSmart (I)
> Varied considerable over the years and between 
states
> Often well below the level for a comprehensive 
program
> Reflecting fiscal constraints in the State/Territories
> The Australian Government for the first time in 
2006/2007 invested $5m; no commitment made 
beyond the initial period.
Investment in SunSmart (II)
 
Table 1: Historical expenditures ($ per capita) on sun protection programs in each current year value and in reference year (2003) values, in 
Victoria (Vic), New South Wales (NSW) and Queensland (Qld) 
Year 1988 1989 1990 1991 1992 1993 1994 1995 1996 1997 1998 1999 2000 2001 2002 2003 2004 2005 2006 
Current Year Value 
VIC  0.26   0.27   0.24   0.28   0.09   0.22   0.22   0.22   0.26   0.26   0.26   0.26   0.15  0.13  0.12  0.20  0.20  0.20  0.19  
NSW -    -    -    -    -    -    -    -    -    -    0.02  0.13  0.15  0.15  0.16  0.13  0.14  0.20  0.24  
QLD -    -    -    -    -    -    -    -    -    -    0.03  0.02  0.02  0.01  0.08  0.07  0.02  0.01  0.02  
Australia  0.25  0.26  0.23  0.28  0.10  0.22  0.22  0.22  0.26  0.26  0.10  0.15  0.12  0.11  0.13  0.14  0.13  0.15  0.17  
In Reference Year (2003) Value 
VIC 0.41 0.40 0.35 0.39 0.12 0.29 0.29 0.28 0.33 0.32 0.31 0.29 0.16 0.14 0.12 0.20 0.19 0.19 0.18 
NSW           0.02 0.08 0.10 0.10 0.10 0.08 0.08 0.12 0.14 
QLD           0.03 0.02 0.03 0.01 0.09 0.07 0.02 0.01 0.02 
Australia  0.41 0.40 0.35 0.39 0.12 0.29 0.29 0.28 0.33 0.32 0.11 0.14 0.10 0.09 0.10 0.12 0.10 0.12 0.12 
Source: provided by the Australian Cancer Council based on information collected from the three State SunSmart programs. 
 
 
Previous Study
> Carter et al (1999) conducted an economic study to 
determine the potential cost-effectiveness of a national 
sun protection program of $5 million investment per 
annum for 20 years 
> Sunburn incidence was used as a proxy for outcome 
measurement in relation to reduction in cancer 
incidence
> The study found the intervention would potentially be 
excellent value-for-money, from the Australian 
Government perspective
Study Objective
> Undertake an economic evaluation of the SunSmart 
program, from the government as a “third-party funder”
perspective to make up-to-date informed policy.
> To demonstrate the C/E of the past SunSmart program
> To determine the potential C/E of an on-going national 
upgraded SunSmart program for the next 20 years
> A broader “health sector” perspective is taken
 as per ACE-Prevention Project to compare across 100 
preventive intervention using the same methodology 
 to recognize the role of individuals in compliance of the 
SunSmart message and ensuring the success of the program
Definition of intervention
> For the past –
 Intervention: a well-resourced SunSmart in Victoria
 Comparator: under-invested states (NSW/Qld)
> For the future 20 years –
 Intervention: an upgraded on-going national SunSmart 
program with an “optimal” investment level as at the historical 
average of Vic. 
 Comparator: a SunSmart program operating at a much lower 
level of investment as at the average of NSW/Qld, reflecting 
current practice
Assessing Program Effectiveness (I)
> Carter et al (1999) used sunburn as a proxy for lifetime UVR 
exposure in relation to reduction in cancer incidence
> Doubt emerging as to its validity, based on a divergent trends in 
observed sunburn incidence and skin cancer incidence
Melbourne sunburn incidence & Victorian melanoma age standardised incidence trends
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Assessing Program Effectiveness (II)
> By analyzing the empirical data on skin cancer 
incidence
> Assess separately for melanoma and NMSC due to 
data availability issues. 
> Melanoma -
 Case numbers by age and gender from 1982 to 2004 from 
three states, i.e. Vic, NSW and Qld
 representative for three latitude zones of different ambient 
UVR exposures (risk factor of skin cancer)
> NMSC –
 national survey results
Assessing Program Effectiveness (III)
> Age-specific incidence rates are calculated for these three zones.
> Compare the melanoma incidence rates pre and post the program
> Projected incidence based on the trend of pre-SunSmart from 1982 to 1987 was 
assumed to be the melanoma incidence without SunSmart
> Effectiveness expressed as rate ratio (RR) of observed over projected incidence
Comparison of melanoma incidence in VIC
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Assessing Program Effectiveness (IV)
> Incidence reduction in Victoria less than the other two states
> Due to lower UVR level?? 
> Adjust for the ‘Slip, Slop, Slap’ effect, 
 assume that the trend in melanoma incidence (slope of increase) in NSW/Qld is 
indicative of the trend in Victoria if they had not had this campaign. 
 Adjusted rate ratios of observed to the expected incidence are then calculated for 
Victoria
 May over-estimate the effectiveness if the lower UVR level in Vic plays a role.
Rate ratio of melanoma incidence before adjustment
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Assessing Program Effectiveness (V)
> More realistic illustration of the past SunSmart in Victoria over “do nothing”
> Enabled the comparison between optimal SunSmart state (Victoria) and under-invested 
SunSmart state (NSW/QLD) over the period 1988 to 2003 
> Incremental effectiveness of the Victorian program compared to NSW/Qld, provides a realistic 
(albeit conservative) estimate of the incremental benefit that a sustained investment in 
SunSmart in the future could achieve compared to current practice
Rate ratio (RR) of observed over predicted melanoma incidence, male 
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Assessing Program Effectiveness (VI)
> NMSC
 Not routinely collected by Cancer Registries
 NMSC incidence has been estimated from a 
population survey every 5 to 7 years since 1985
 Staples (1998) reported the incidence of BCC has 
fallen in the younger age groups less than 50 years 
old
 Appears to be no impact on SCC
Modeling to health outcomes
> Assumption –
 the reduction in melanoma incidence that has occurred in the 
past in Victoria could be re-produced by the optimal 
SunSmart program for Australia as a whole in the next 20 
years
> Outcomes –
 Incidence reduction 
 Death averted
 Life Years Saved (LYS)
 Disability Adjusted Life Years (DALY): health loss due to 
• mortality component (HALY) 
• morbidity component (YLD) 
• using the Australian Burden of Disease (BoD) results
Cost of intervention and 
potential offsets
> For the past –
 Actual expenditures spent
> For the future –
 Intervention: $0.28 per capita, historical average of the Vic 
SunSmart expenditure
 Comparator: $0.07 per capita, average level of investment in 
NSW/Qld over the last decade (1998-2006),
> Cost offsets refers to the savings in the costs of management 
and treatment for skin cancer
 Melanoma: $3341 per case
 NMSC: $700 per case (2001 value, AIHW 2005)
> Cost to individuals: $3 per capita per year 
> Reference year: 2003
> All costs and outcomes are discounted at 3% p.a.
Sensitivity/Uncertainty Analyses
> Main source of the uncertainty would be around the assumptions we make 
for assessing the effectiveness
> One-way sensitivity analysis on
 Program effectiveness on melanoma: 50% and 100%.
 Discount rate, where the base rate of 3% is varied to 0%, 5%, 7%. 
 Decay rate of program effectiveness on NMSC: 0%, 10%, 20% per annum.
> Threshold analysis to to determine the proportion of health gain that would 
need to be attributed to SunSmart for the program to no longer be 
dominant or reach a threshold 
> Multiple-probabilistic uncertainty analysis around costs using @Risk 
software
Uncertainty analysis parameters and distribution 
Parameter Base case value (range) Distribution 
Program cost of intervention $0.28 per capita (0.28 – 0.55) Triangular 
Program cost of comparator $0.07 per capita (0.07-0.14) Triangular 
Cost offset of Melanoma $3747 per case (+/-10%) Uniform 
Cost offset of NMSC $785 per case (+/-10%) Uniform 
 
 
Results (I): past
> The past SunSmart program in Victoria since it was 
introduced in 1988 to 2003 achieves dominance: 
achieves health gains and saves money, from the 
Government perspective.
> Excluding cost-offset:
 $680 per LYS 
 $540 per DALY averted
Results (II): future
 
The median value and 95% uncertainty interval of ICER results in the base case analysis 
(d=3%) for both perspectives. 
 Government Perspective Health Sector Perspective 
Health gains median value (95% UI) median value (95% UI) 
Incidence case prevented 191,000 191,000 
Life years saved (LYS) 91,000 91,000 
DALYs averted 122,000 122,000 
Incremental cost   
Incremental net costs $-180m ($-220m, $-120m) $770m ($730m, $830m) 
Incremental program cost $85m ($57m,$140m) $1,000m ($1,000m, $1,100m) 
Incremental cost offsets  $270m ($240m, $290m) $270m ($240m, $290m) 
ICER per LYS   
ICER (with cost-offset) dominant $8,500($8,000, $9,100) 
ICER (without cost-offset) $940($610,$1500) $11,400 ($11,100, $12,000) 
ICER per DALY averted   
ICER (with cost-offset) dominant $6,349 ($5,971, $6,821) 
ICER (without cost-offset) $700 ($470,$1100) $8,500 ($8,300, $8,900) 
Investment return   
Program cost  $115m ($90m, $160m) $1,070m ($1,040m, $1,120m) 
Investment return for every 
dollar invested by government 
$2.30 ($1.60, $3.00)  
 
Results (III): Sensitivity Analysis
> From Government perspective, all ICER of the sensitivity result 
are dominant with cost-offsets
> Worse case scenario where we assume the future national 
SunSmart: 
 only achieves 50% of the effectiveness in melanoma incidence 
reduction 
 with double the program cost as the past SunSmart in Victoria
 together with a greater decay rate of 20% in the ability of the 
program to reduce the rate of NMSC
 ICER: 129/DALY averted with cost-offsets
> Threshold analysis 
 <2% of the reduction attributed to SunSmart in order for dominance 
to be maintained (Govt perspective, including cost-offsets) 
 17% of the reduction attributed to SunSmart for ICER< 
50,000/DALY (health sector perspective, including cost-offsets)
Results (IV): Acceptability Curve
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Discussion
> Provide evidence to support a recommendation for a national 
comprehensive SunSmart program.
> Results are similar in nature and magnitude to the previous Australian 
work evaluating the cost-effectiveness of SunSmart (Carter, Marks et al. 
1999).
> Quality of evidence is not perfect but it is considered the best we could 
obtain - threshold analysis 
> Allocative efficiency vs. Technical efficiency
> Unnecessary cost in removal and biopsy of non-malignant skin moles is 
not modelled
> Future SunSmart will need to manage a more complex message in 
which the risks of skin cancer are balanced alongside the necessary 
levels of sunlight in relation to Vitamin D deficiency
